Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.720
-0.060 (-3.37%)
At close: Sep 15, 2026, 4:00 PM EDT
1.740
+0.020 (1.16%)
After-hours: Sep 15, 2026, 7:50 PM EDT

Allogene Therapeutics Revenue

Allogene Therapeutics had revenue of $4.64M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $4.64M.

Revenue (ttm)
$4.64M
Revenue Growth
n/a
P/S Ratio
128.07
Revenue / Employee
$30,526
Employees
152
Market Cap
594.24M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025---
Dec 31, 202422.00K-73.00K-76.84%
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
CorMedix462.25M
Valneva SE163.30M
Verastem87.53M
Assembly Biosciences74.85M
OmniAb38.46M
Oculis Holding AG1.45M
Shattuck Labs1.00M
Altimmune31.00K
Revenue Rankings